Skip to main content
SpringerLink
Log in

Allogeneic stem cell transplantation in patients with a prior history of prostate cancer

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

A retrospective analysis of 25 patients with a history of prostate cancer (PC) who subsequently underwent allogeneic hematopoietic cell transplantation (HCT) for treatment of a hematologic malignancy was performed. Median patient age was 66.7 years. Median duration from the diagnosis of PC to HCT was 4.2 years. Twenty-three patients had Gleason group 1 or 2 disease. Therapy included prostatectomy (n = 13) and external beam or brachytherapy (n = 9). Hematologic diagnoses included both myeloid (n = 15) and lymphoid neoplasms (n = 10). Twenty-four patients received either a nonmyeloablative or reduced intensity conditioning regimen. GVHD prophylaxis included a calcineurin inhibitor and mycophenolate mofetil ± sirolimus. Twenty patients had HLA-matched sibling or HLA-matched unrelated donors; five patients had HLA-mismatched donors. Eleven patients are alive, and 14 have died. Median survival was 2.5 years (range, .02–12.6 years). The major cause of death was hematologic relapse. Only one patient had evidence of recurrent PC, occurring 1.5 years posttransplant. In carefully selected patients with a prior history of PC, there was no evidence of rapid recurrence of the solid tumor (ST) after HCT. PC patients who are in remission from their ST or have control of their disease on therapy should be considered eligible for HCT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Majhail NS, Farnia SH, Carpenter PA, Champlin RE, Crawford S, Marks DI et al (2015) Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 21(11):1863–1869. https://doi.org/10.1016/j.bbmt.2015.07.032

    Article  Google Scholar 

  2. Muffly L, Pasquini MC, Martens M, Brazauskas R, Zhu X, Adekola K et al (2017) Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. Blood 130(9):1156–1164. https://doi.org/10.1182/blood-2017-03-772368

    Article  CAS  Google Scholar 

  3. Zuckerman T (2017) Allogeneic transplant: does age still matter? Blood 130(9):1079–1080. https://doi.org/10.1182/blood-2017-07-795948

    Article  CAS  Google Scholar 

  4. Ehrhardt MJ, Brazauskas R, He W, Rizzo JD (2016) Shaw BE 2016 Survival of patients who develop solid tumors following hematopoietic stem cell transplantation. Bone Marrow Transplant 51(1):83–88. https://doi.org/10.1038/bmt.2015.203

    Article  CAS  Google Scholar 

  5. Socie G, Rizzo JD (2012) Second solid tumors: screening and management guidelines in long-term survivors after allogeneic stem cell transplantation. Semin Hematol 49(1):4–9. https://doi.org/10.1053/j.seminhematol.2011.10.013

    Article  Google Scholar 

  6. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106(8):2912–2919. https://doi.org/10.1182/blood-2005-05-2004

    Article  CAS  Google Scholar 

  7. Sorror ML (2010) Comorbidities and hematopoietic cell transplantation outcomes. Hematology Am Soc Hematol Educ Program 2010:237–247. https://doi.org/10.1182/asheducation-2010.1.237

    Article  Google Scholar 

  8. Siegel RL, Miller KD, Fuchs HE (2021) Jemal A 2021 Cancer statistics. CA Cancer J Clin 71(1):7–33. https://doi.org/10.3322/caac.21654

    Article  Google Scholar 

  9. Negoita S, Feuer EJ, Mariotto A, Cronin KA, Petkov VI, Hussey SK et al (2018) Annual report to the nation on the status of cancer, part II: recent changes in prostate cancer trends and disease characteristics. Cancer 124(13):2801–2814. https://doi.org/10.1002/cncr.31549

    Article  Google Scholar 

  10. Etzioni R, Gulati R (2016) Recent trends in PSA testing and prostate cancer incidence: a look at context. JAMA Oncol 2(7):955–956. https://doi.org/10.1001/jamaoncol.2015.6310

    Article  Google Scholar 

  11. Fedewa SA, Ward EM, Brawley O, Jemal A (2017) Recent patterns of prostate-specific antigen testing for prostate cancer screening in the United States. JAMA Intern Med 177(7):1040–1042. https://doi.org/10.1001/jamainternmed.2017.0340

    Article  Google Scholar 

  12. Ham WS, Chalfin HJ, Feng Z, Trock BJ, Epstein JI, Cheung C et al (2017) New prostate cancer grading system predicts long-term survival following surgery for Gleason score 8–10 prostate cancer. Eur Urol 71(6):907–912. https://doi.org/10.1016/j.eururo.2016.11.006

    Article  Google Scholar 

  13. Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY et al (2019) Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol 20(5):686–700. https://doi.org/10.1016/S1470-2045(19)30082-8

    Article  CAS  Google Scholar 

  14. Rizzo JD, Curtis RE, Socie G, Sobocinski KA, Gilbert E, Landgren O et al (2009) Solid cancers after allogeneic hematopoietic cell transplantation. Blood 113(5):1175–1183. https://doi.org/10.1182/blood-2008-05-158782

    Article  CAS  Google Scholar 

  15. Woodle ES, Gupta M, Buell JF, Neff GW, Gross TG, First MR et al (2005) Prostate cancer prior to solid organ transplantation: the Israel Penn International Transplant Tumor Registry experience. Transplant Proc 37(2):958–959. https://doi.org/10.1016/j.transproceed.2004.12.127

    Article  CAS  Google Scholar 

  16. Rossi AP, Klein CL (2019) Posttransplant malignancy. Surg Clin North Am 99(1):49–64. https://doi.org/10.1016/j.suc.2018.09.004

    Article  Google Scholar 

  17. Chamie K, Ghosh PM, Koppie TM, Romero V, Troppmann C (2008) deVere White RW 2008 The effect of sirolimus on prostate-specific antigen (PSA) levels in male renal transplant recipients without prostate cancer. Am J Transplant 8(12):2668–2673. https://doi.org/10.1111/j.1600-6143.2008.02430.x

    Article  CAS  Google Scholar 

  18. Wu L, Birle DC, Tannock IF (2005) Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res 65(7):2825–2831. https://doi.org/10.1158/0008-5472.CAN-04-3137

    Article  CAS  Google Scholar 

  19. Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M et al (1999) Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 397(6719):530–534. https://doi.org/10.1038/17401

    Article  CAS  Google Scholar 

  20. Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD (2005) Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 80(7):883–889. https://doi.org/10.1097/01.tp.0000184006.43152.8d

    Article  CAS  Google Scholar 

  21. Del Re M, Fogli S, Derosa L, Massari F, De Souza P, Crucitta S et al (2017) The role of drug-drug interactions in prostate cancer treatment: focus on abiraterone acetate/prednisone and enzalutamide. Cancer Treat Rev 55:71–82. https://doi.org/10.1016/j.ctrv.2017.03.001

    Article  CAS  Google Scholar 

  22. Benoist GE, Hendriks RJ, Mulders PF, Gerritsen WR, Somford DM, Schalken JA et al (2016) Pharmacokinetic aspects of the two novel oral drugs used for metastatic castration-resistant prostate cancer: abiraterone acetate and enzalutamide. Clin Pharmacokinet 55(11):1369–1380. https://doi.org/10.1007/s40262-016-0403-6

    Article  CAS  Google Scholar 

  23. Fay EK, Graff JN (2020) Immunotherapy in prostate cancer. Cancers (Basel) 12(7). https://doi.org/10.3390/cancers12071752

  24. Chen S, Zhang Z, Zheng X, Tao H, Zhang S, Ma J (2021) Response efficacy of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. Front Oncol 11:562315. https://doi.org/10.3389/fonc.2021.562315

    Article  Google Scholar 

  25. Ijaz A, Khan AY, Malik SU, Faridi W, Fraz MA, Usman M et al (2019) Significant risk of graft-versus-host disease with exposure to checkpoint inhibitors before and after allogeneic transplantation. Biol Blood Marrow Transplant 25(1):94–99. https://doi.org/10.1016/j.bbmt.2018.08.028

    Article  CAS  Google Scholar 

  26. Mielcarek M, Furlong T, O’Donnell PV, Storer BE, McCune JS, Storb R et al (2016) Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation. Blood 127(11):1502–1508. https://doi.org/10.1182/blood-2015-10-672071

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors wish to acknowledge Chris Davis for his help in accessing transplantation data for this patient population.

Author information

Authors and Affiliations

  1. Clinical Research Division, Fred Hutchinson Cancer Center, 1100 Fairview Ave. N., D5-280, PO Box 19024, Seattle, WA, 98109-1024, USA

    Raffaele Palmieri & Kristine Doney

  2. Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy

    Raffaele Palmieri

  3. Department of Medicine, Division of Oncology, University of Washington Medical Center, Seattle, WA, USA

    Robert B. Montgomery & Kristine Doney

  4. VA Puget Sound, Seattle, WA, USA

    Robert B. Montgomery

Authors
  1. Raffaele Palmieri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert B. Montgomery
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kristine Doney
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kristine Doney.

Ethics declarations

Ethics approval

Approval was obtained from the Institutional Review Board of the Fred Hutchinson Cancer Research Center. The procedures used in this study adhere to the tenets of the Declaration of Helsinki.

Consent to participate

Informed consent was obtained from all patients and donors included in the study.

Competing interests

The authors declare no competing interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Palmieri, R., Montgomery, R.B. & Doney, K. Allogeneic stem cell transplantation in patients with a prior history of prostate cancer. Ann Hematol 102, 407–412 (2023). https://doi.org/10.1007/s00277-022-05041-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-022-05041-0

Keywords

Search

Navigation